

## Future-proof your HCP strategy.

Robust and accurate HCP measurement is crucial throughout biologics development.

From sample preparation to data analysis, each step affects the next — and ultimately, your results.



Four questions to help you decide if your HCP analysis data is accurate, robust, and ready for next phase approval.



CV between a minimum of three dilutions should be < 20%.

You are off to a good start!

Well that was a rough start!

Below 20% means your assay is compatible.

Above 20% means your assay is not compatible.

Challenge your current HCP ELISA against another manufacturer.



Recovery of known HCP concentration must be within 80% to 120% to be valid.

Now you are just showing off!

Within 80% to 120% means your assay is accurate.

Back you go!

. . . . . . . . . . . . .

Outside 80% to 120% means your assay is not accurate.

Challenge your current HCP ELISA against another manufacturer.

## Is your assay reproducible?



-----



Have you done this before?

Below 20% means your sample is reproducible. We all know what happens next...

Above 20% means your sample is not reproducible.

Challenge your current HCP ELISA against another manufacturer.

## Is your HCP antibody coverage sufficient?



## Submit your accurate and robust data for next phase approval.

We understand that HCP control requires more than a product. It requires a strategy.

Whether your HCP detection is outsourced or managed in-house, our solution is to lead with quality, reliability, and efficiency across the entire workflow — giving you the confidence that your results are robust and reproducible.

- ELISA kits and coverage workflow
- Equipment
- 2D consumables
- Software
- Training
- Scientific support

Cytiva and the Drop logo are trademarks of Global Life Sciences IP Holdco LLC or an affiliate.

DIBE is a trademark of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva.

© 2020 Cytiva CY13370-25AUG20-IG